Immune OTC Stock Performance

IMUN -  USA Stock  

USD 1.94  0.04  2.11%

Immune Therapeutics holds a performance score of 4 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 3.5583, which attests to a somewhat significant risk relative to the market. Let's try to break down what Immune's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immune Therapeutics will likely underperform. Although it is vital to follow Immune Therapeutics current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. Our philosophy towards determining future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Immune Therapeutics expected return of 1.24 will be sustainable into the future, we have found twenty-six different technical indicators, which can help you to check if the expected returns are sustainable. Use Immune Therapeutics treynor ratio, as well as the relationship between the semi variance and rate of daily change to analyze future returns on Immune Therapeutics.

Immune O TC Stock Performance 

Immune Performance
4 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Immune Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Immune Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more

Immune Price Channel

Quick Ratio0.26
Fifty Two Week Low1.0200
Fifty Two Week High32.7000

Immune Therapeutics Relative Risk vs. Return Landscape

If you would invest  217.00  in Immune Therapeutics on October 29, 2021 and sell it today you would lose (23.00)  from holding Immune Therapeutics or give up 10.6% of portfolio value over 90 days. Immune Therapeutics is currently generating 1.2352% in daily expected returns and assumes 19.3018% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Immune, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Immune Therapeutics is expected to generate 22.9 times more return on investment than the market. However, the company is 22.9 times more volatile than its market benchmark. It trades about 0.06 of its potential returns per unit of risk. The DOW is currently generating roughly -0.09 per unit of risk.

Immune Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Immune Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Immune Therapeutics, and traders can use it to determine the average amount a Immune Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.064

Good Returns
Average Returns
Small ReturnsIMUN
Negative Returns
Estimated Market Risk
  actual daily
 96 %
of total potential
Expected Return
  actual daily
 23 %
of total potential
Risk-Adjusted Return
  actual daily
 4 %
of total potential
Based on monthly moving average Immune Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immune Therapeutics by adding it to a well-diversified portfolio.

About Immune Therapeutics Performance

To evaluate Immune Therapeutics OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Immune Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Immune OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Immune Therapeutics stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Immune's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Immune Therapeutics, Inc. focuses on the development, approval, and commercialization of pharmaceutical products. Immune Therapeutics, Inc. was incorporated in 1993 and is headquartered in Orlando, Florida. Immune Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.

Things to note about Immune Therapeutics

Checking the ongoing alerts about Immune Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Immune Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Immune Therapeutics Alerts

Equity Alerts and Improvement Suggestions

Immune Therapeutics is way too risky over 90 days horizon
Immune Therapeutics may become a speculative penny stock
Immune Therapeutics appears to be risky and price may revert if volatility continues
The company currently holds 3.31 M in liabilities with Debt to Equity (D/E) ratio of 1.97, which is about average as compared to similar companies. Immune Therapeutics has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due.
Immune Therapeutics currently holds about 2.69 M in cash with (250.58 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.57, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 17.0% of Immune Therapeutics shares are held by company insiders
Latest headline from Apollon Formularies Announces Appointment of Dr. the Honorable Archibald McDonald, Professor Emeritus, and Former University Dean, Faculty of Medical Sciences and Pro-Vice Chancellor, University of the West Indies as Director of Clinical Trials - Yahoo Finance
Please see Risk vs Return Analysis. Note that the Immune Therapeutics information on this page should be used as a complementary analysis to other Immune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Immune OTC Stock analysis

When running Immune Therapeutics price analysis, check to measure Immune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immune Therapeutics is operating at the current time. Most of Immune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immune Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immune Therapeutics' price. Additionally, you may evaluate how the addition of Immune Therapeutics to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
CEO Directory
Screen CEOs from public companies around the world
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Bond Directory
Find actively traded corporate debentures issued by US companies
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Immune Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immune Therapeutics. If investors know Immune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immune Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immune Therapeutics is measured differently than its book value, which is the value of Immune that is recorded on the company's balance sheet. Investors also form their own opinion of Immune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immune Therapeutics' market value can be influenced by many factors that don't directly affect Immune Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immune Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.